The Comparative Effectiveness Dementia & Alzheimer's Registry
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 452
- 试验地点
- 1
- 主要终点
- Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months
研究概览
简要总结
To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.
详细描述
The Comparative Effectiveness Dementia & Alzheimer's Registry (CEDAR) Project is a prospective, observational registry of adult patients at-risk for, or with, a diagnosis of dementia due to Alzheimer's disease (AD) or other neurodegenerative dementias. The purpose of this study is to develop a research repository, or database, for information collected during routine medical care of people with normal memory and family history of AD, or with memory loss or other changes in thinking. The registry will help generate empirical evidence that improves knowledge and informs care decisions about risk reduction for dementia due to AD, and about the effectiveness of a clinical precision medicine intervention. Using a life course approach to comparative effectiveness research will enable investigators to analyze the effects of evidence-based multidomain interventions on cognition, biomarkers of AD risk, and calculated AD risk across the pre-dementia spectrum of AD.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18 years of age or older
- •family history of Alzheimer's disease and no cognitive complaints OR subjective cognitive decline OR preclinical AD OR mild cognitive impairment due to AD or other conditions
排除标准
- 未提供
结局指标
主要结局
Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months
时间窗: every 6 months, for 18 months
Composite Cognitive Battery (including NIH Toolbox Cognition Battery and other pen-and-paper neuropsychological tests).
次要结局
- Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.(18 months)
- Change from Baseline in Homocysteine at 18 months(18 months)
- Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months(18 months)
- Change from Baseline in Cognitive Aging Composite (CAC) every 6 months(every 6 months, for 18 months)
- Change from Baseline in Inflammatory Biomarkers at 18 months(18 months)
- Change from Baseline in Metabolism Biomarkers at 18 months(18 months)
- Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months(6 months)
- Change from Baseline in Cholesterol Biomarkers at 18 months(18 months)
- Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months(18 months)
- Change from Baseline in Vitamin D at 18 months(18 months)